Systemic lupus erythematosus in childhood

Rheumatic Disease Clinics of North America

Volumn 28, Issue 3, 2002, Pages 561-577

  Klein Gitelman, Marisa ^a   Reiff, Andreas ^b   Silverman, Earl D ^c  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; OSTEOPOROSIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION;

EID: 0036697767     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00015-7     Document Type: Review

References (113)

1. Glidden RS, Mantzouranis E, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983;29:196-210.
2. King KK, Kornreich HK, Bernstein BH, Singsen BH, Hanson V. The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum 1977;20:287-94.
3. Meislin AG, Rothfield N. Systemic lupus erythematosus in childhood: analysis of 42 cases with comparative data in 200 adult cases followed concurrently. Pediatr 1968;42:37-49.
4. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome of systemic lupus erythematosus. I. Entry variables as predictors of progress. Arthritis Rheum 1982;25:601-11.
5. Abeles M, Urman JD, Weisntein A, et al. Systemic lupus erythematosus in the younger patient: survival studies. J Rheumatol 1980;7:515-22.
6. Lehman TJA, McCurdy D, Spencer C, et al. Prognostic value of antibodies to Ro/SSA, SSB/La and RNP in children with systemic lupus erythematosus. Arthritis Rheum 1990;33:S154.
7. Wallace DJ, Podell T, Weiner J, et al. Systemic lupus erythematosus survival patterns. Experience with 609 patients. JAMA 1981;245:934-8.
8. Garin E, Shulman ST, Donnelly WH, Richard GA. Systemic lupus erythematosus glomerulonephritis in children. Pediatr 1981;10:351-67.
9. Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981;24:1389-95.
10. Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993;36:348-54.
11. Gloor JM. Lupus nephritis in children. Lupus 1998;7:639-43.
12. Tucker LR, Menon S, Schaller JG, Isenberg DA. Adult and childhood onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br J Rheumatol 1995;34:866-72.
13. Blanco FJ, de la Mata J, Gomez-Reino JJ, et al. Clinical and serological manifestations of 307 Spanish patients with systemic lupus erythematosus. Comparison with other ethnic groups. Rev Clin Esp 1995;195:534-40.
14. Vilarinho ST, Costallat L. Evaluation of the hypothalamic-pituitary-gonadal axis in males with systemic lupus erythematosus J Rheumatol 1998;25:1097-103.
15. Rood MJ, Van Deer Velde EA, Ten Cate R, Breedveld VC, Huizinga TWJ. Female sex hormones at the onset of systemic lupus erythematosus affect survival. Br J Rheumatol 1998;37:1008-10.
16. van Vollenhoven RE, Engleman ED, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
17. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998;25:285-9.
18. Prystowsky SD, Herndon JH, Gilliam JN. Chronic cutaneous lupus erythematosus (DLE). Medicine (Baltimore) 1975;55:183-91.
19. Dubois EL. Lupus erythematosus. 4th edition. Philadelphia: Lea and Feibiger Press; 1993.
20. Sorof JM, Perez MD, Brewer ED, Hawkins EP, Warren RW. Increasing incidence of childhood class V lupus nephritis. J Rheumatol 1998;25:1413-8.
21. Gare BA. Epidemiology of rheumatic disease in children. Curr Opin Rheumatol 1996;8(5): 449-54.
22. Donadio JV, Hart GM, Bergstrahl EJ, et al. Prognostic determinations in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4:109-15.
23. Graham TB, Lovell DJ. Outcome in pediatric rheumatic disease. Curr Opin Rheumatol 1997;9: 434-9.
24. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994;8:230-49.
25. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
26. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989;114: 1055-60.
27. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
28. Silverman E. What's new in the treatment of pediatric SLE? J Rheumatol 1996;23:1657-60.
29. Valeri A, Radhakrishnan J, Estes D, D'Agati V, Pirani C, Appel GB. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-8.
30. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatol 2000;39:969-74.
31. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996;7:924-9.
32. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-8.
33. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol 2000;14:158-66.
34. Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol 1999; 19:2-11.
35. Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7:299-305.
36. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
37. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intem Med 1995;122:940-50.
38. Dooley MA, Hogan S, Jennett CJ, Falk RJ. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
39. Austin AH, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;19:1670-8.
40. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-9.
41. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-6.
42. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
43. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-8.
44. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of antiinterleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
45. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;28:95-101.
46. Szer IS. The diagnosis and management of systemic lupus erythematosus in childhood. Pediatr Ann 1986;15:596-604.
47. ACR Ad Hoc Committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus Arthritis Rheum 1999;42:599-608.
48. Rosenberg AM. Systemic lupus erythematosus in children. Sem Immunopathol 1994;16: 261-79.
49. Amit M, Molad Y, Levy O, Wysenbeek AJ. Headache in systemic lupus erythematosus and its relation to other disease manifestations. Clin Exp Rheumatol 1999; 17:467-70.
50. Uziel Y, Laxer RM, Blaser S, Andrew M, Schneider R, Silverman ED. Cerebral vein thrombosis in childhood systemic lupus erythematosus. J Pediatr 1995;126:722-7.
51. Padeh S, Passwell JH. Systemic lupus erythematosus presenting as idiopathic intracranial hypertension. J Rheumatol 1996;23:1266-8.
52. Papero PH, Bluestein HG, White P, Lipnick RN. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheum 1990;8:417-24.
53. Wyckoff PM, Miller LC, Tucker LB, Schaller JG. Neuropsychological assessment of children and adolescents with systemic lupus erythematosus. Lupus 1995;4:217-20.
54. Klein-Gitelman MS, Wagner-Weiner L, Kress A, Hunter S, Zelko F. Comparison of neurocognitive function in children with SLE without overt neurologic disease to their peers: a case control evaluation. Arthritis Rheum 2001;44:S384.
55. Zwaifler NJ, Bluestein HG. The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 1982;25:862-6.
56. Wilson HA, Winfield JB, Lahita RG, Koffler D. Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum 1979;22: 458-62.
57. Bluestein HG. Neurocytotoxic antibodies in the serum of patients with SLE. Proc Nat Acad Sci. USA 1978;75:3965.
58. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981;70:240-6.
59. How A, Dent PB, Liao S-K, Denbeug JA. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1985;28:789-95.
60. Robbins ML, Kornguth SE, Bell CL, Kalinke T, England D. Antineurofilament antibody evaluation in neuropsychiatiric systemic lupus erythematosus: combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum 1988;31:623-31.
61. Press J, Palayew K, Laxer RM, Elkon K, Eddy A, Rakoff D, Silverman ED. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996;39:671-6.
62. Tincani A, Brey R, Balestrieri G, Vitali C, Doria A, Galeazzi M, et al. International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatric manifestations. Clin Exp Rheum 1996;14:S23-29.
63. Reiff A, Miller J, Shaham B, Bernstein B, Szer IS. Childhood central nervous system lupus: longitudinal assessment using single photon emission computed tomography. J Rheumatol 1997;24:2461-5.
64. Lin WY, Lan JL, Yen TC, Wang SJ. Technetium-99m-HMPAO brain SPECT in systemic lupus erythematosus with CNS involvement. J Nucl Med 1997;38:1112-5.
65. Russo R, Gilday D, Laxer RM, Eddy A, Silverman ED. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998;25: 576-82.
66. Turkel SB, Miller JH, Reiff A. Case series: neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J Amer Acad Child Adolesc Psychiatr 2001;40:482-5.
67. Ragsdale CG, Petty RE, Cassidy JT, Sullivan DB. The clinical progression of apparent juvenile rheumatoid arthritis to systemic lupus erythematosus. J Rheumatol 1980;7:50-5.
68. Saulsbury FT, Kesler RW, Kennaugh JM, Barber JC, Chevalier RL. Overlap syndrome of juvenile rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1982;9:610-2.
69. Citera G, Espada G, Maldonado, Cocco JA. Sequential development of two connective tissue diseases in juvenile patients. J Rheumatol 1993;20:2149-52.
70. Zetterstrom R, Bergland G. Systemic lupus erythematosus in childhood: a clinical study. Paediatrica 1956;5:189-204.
71. Cook CD, Wedgewood RJT, Craig JM, Hartman JR, Janeway CA. Systemic lupus erythematosus: description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatr 1960;26:570-85.
72. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971;50:85-95.
73. Abeles M, Urman JD, Weinstein A, Lowenstein M, Rothfield NF. Systemic lupus erythematosus in the younger patient: survival studies. J Rheumatol 1980;7:515-22.
74. Caeiro F, Michielson FMC, Bernstein R, Hughes GRV, Ansell BM. Systemic lupus erythematosus in childhood. Ann Rheum Dis 1981;40:325-31.
75. Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982;2:S212-222.
76. Lacks S, White P. Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 1990;17:941-5.
77. Gladman DD, Ginzler E, Goldsmith CH, Fortin P, Liang M, Urowitz MB, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
78. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum, in press.
79. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998;18:45-9.
80. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001;28: 102-8.
81. Redlich K, Ziegler S, Kiener HP, et al. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59:308-10.
82. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995;8:137-45.
83. Klein-Gitelman MS, Shore R, Peterson K, Pachman LM. Bone mineral density (BMD) at diagnosis and after treatment (TX) of pediatric systemic lupus erythematosus. Arthritis Rheum 1996;39:S188.
84. Pillersdorf S, Sebaldt RJ, Tugwell P, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a three year follow-up. J Rheumatol 1996;23:995-1000.
85. Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol 1996;103: 91-3.
86. Eberhard BA, Laxer RM, Eddy AA, Silverman ED. Presence of thyroid abnormalities in children with systemic lupus erythematosus. J Pediatr 1991;119:277-9.
87. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
88. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A. Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis 1998;32:825-8.
89. Stephan JL, Jeannoel P, Chanoz J, Gentil-Perret A. Epstein-Barr virus-associated Kikuchi disease in two children. Am J Pediatr Hematol Oncol 2001;23:240-3.
90. Moore TL, Bandlamudi R, Alam SM, Nesher G. Parvovirus infection mimicking systemic lupus erythematosus in a pediatric population. Semin Arthritis Rheum 1999;28:314-8.
91. Trapani S, Ermini M, Falcini F. Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 1999;28:319-25.
92. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1999;41:1828-34.
93. Hill MD, Karsh J. Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature. Arthritis Rheum 1997;40:1716-9.
94. McDonald E, Jarrett MP, Schiffman G, Grayzel A.I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984;11: 306-8.
95. Jarrett MP, Schiffman G, Barland P, Grayzel Al. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980;23:1287-93.
96. Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD, Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979; 22:1321-5.
97. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000;27:1681-5.
98. Brodman R, Gilfillan R, Glass D, Schur PH. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978;88:735-40.
99. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 1978; 88:729-34.
100. Ioannou Y, Isenberg DA. Immunization of patients with systemic lupus erythematosus: the current state of play. Lupus 1980;8:497-501.
101. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001;10:237-40.
102. Ward MM, Dawson DV, Kredich DW, Pisetsky DS. Expression of IgM and IgG autoantibodies in pediatric and adult systemic lupus erythematosus. Clin Immunol Immunopath 1990;55: 273-84.
103. Shergy WJ, Kredich DW, Pisetsky. The relationship of anticardiolipin antibodies to disease manifestations in pediatrics systemic lupus erythematosus. J Rheumatol 1988;15:1389-94.
104. Reveille JD, Arnett FC, Wilson RW, Bias WB, McLean RH. Null alleles of the fourth component of complement and HLA haplotypes in familial systemic lupus erythematosus. Immunogenetics 1985;21:299-311.
105. Steinsson K, Amason A, Erlendsson K, et al. A study of the major histocompatibilty complex in a Caucasian family with multiple cases of systemic lupus erythematosus: association with the C4AQ0 phenotype. J Rheumatol 1995;22:1862-6.
106. Hong GH, Kim HY, Takeuchi F, et al. Association of complement C4 and HLA-DR alleles with systemic lupus erythematosus in Koreans. J Rheumatol 1994;21:442-7.
107. Moulds JM, Warner NB, Arnett FC. Complement component C4A and C4B levels in systemic lupus erythematosus: quantitation in relation to C4 null status and disease activity. J Rheumatol 1993;20:443-7.
108. Foeldvari I, Kimura Y, Jacobs JC. Congenital complement deficiency in childhood lupus: 17% require little or no treatment. Arthritis Rheum 1990;33S:S144.
109. Agnello V, DeBracco MME, Kunkel HG. Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol 1972;108:837-40.
110. Gewurz A, Lint TF, Robert JL, et al. Homozygous C2 deficiency with fulminant lupus erythematosus. Arthritis Rheum 1978;21:28-36.
111. Schaller J. Illness resembling lupus erythematosus in mothers of boys with chronic granulomatous disease. Ann Intern Med 1972;76:747-50.
112. Cassidy JT, Burt A, Petty R, Sullivan D. Selective IgA deficiency in connective tissue diseases. N Engl J Med 1969;280:275.
113. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa receptor (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100:1059-70.